About "Pharmaceuticals & life science"
The PwC pharmaceuticals and life science practice provides professional services to leading pharmaceuticals and life science organizations.
More about this author
WebcastPharmaceutical & Life Sciences Tax Hot Topics webcast: Medical Device Excise Tax - September 23, 2014
9/15/14 | Pharmaceuticals & life science
Please join PwC for a complimentary Pharmaceutical and Life Sciences Tax Technical Hot Topics webcast: Federal Medical Device Excise Tax (MDET); including a Legislative Update, IRS Audit Program and Planning Opportunities on Tuesday, September 23, 2014 from 12:00pm - 1:00pm (US ET).
WebcastRevenue Recognition Webcast & Industry Supplement - Pharmaceutical and Life Sciences Companies - June 25, 2014
6/11/14 | Pharmaceuticals & life science
Join us for an expanded discussion on the specific impacts the new revenue recognition standard will have on the Pharmaceutical and Life Sciences industry and download our P&LS Industry Supplement.
- IPR&D acquired in a business combination – How many pieces?
5/21/14 | Pharmaceuticals & life science
This Pharmaceutical and Life Sciences Alert focuses on in-process research and development (IPR&D) in acquisition accounting.
- Potential impacts to Pharma and Life Sciences companies of the new accounting definition of an "investment company"
4/10/14 | Pharmaceuticals & life science
This Pharmaceutical and Life Sciences Alert focuses on the key accounting considerations when assessing whether an entity is an investment company under the new accounting definition and provides illustrative examples.
- Rx Marketplace Quarterly Newsletter
3/27/14 | Pharmaceuticals & life science
The PwC Rx Marketplace Quarterly features a wide range of financial reporting developments, accounting and tax developments, regulatory updates and general industry trends impacting the pharmaceutical and life sciences industry. Each quarterly also shares strategies that companies can use to unlock divestiture value, as well as links to publications and online resources. In the spotlight in this issue is our summary of the IPO market, which has seen its most robust year since 2007. We cover key metrics for the past year, assess the industry’s top registrants, and offer a snapshot of IPO activity during the first two months of 2014.
- Pharmaceutical Commerce: Top health industry issues for life sciences in 2014
3/25/14 | Pharmaceuticals & life science
Pharmaceutical Commerce: Top health industry issues for life sciences in 2014
- Distinguishing a Business from an Asset or a Group of Assets
1/16/14 | Pharmaceuticals & life science
This Pharmaceutical and Life Sciences Industry GAAP Alert focuses on the key accounting considerations when making this determination and provides illustrative examples.
Accounting guidesUS GAAP: Issues and solutions for pharmaceuticals and life sciences industry
11/20/13 | Pharmaceuticals & life science
This publication highlights factors the industry should consider and provides guidance on the most pertinent accounting solutions under US GAAP. The solutions presented are meant to provide a framework for determining the appropriate accounting answer for general solutions.
- Customer experience in the pharmaceutical sector: Getting closer to the patient
11/19/13 | Pharmaceuticals & life science
As patients exert greater control over their healthcare, drug makers need to master the complexities of consumer behavior to demonstrate value in the new health economy. Consumers are willing to offer feedback that informs who they are, how they behave and how existing biases impact their behavior. Drug makers that tap into this feedback will reach a new level of success.
- Contingent Consideration in a Business Combination
10/16/13 | Pharmaceuticals & life science
This Pharmaceutical and Life Sciences Industry Alert provides guidance on the accounting for contingent consideration arrangements in business combinations.
10Minutes10Minutes on drug value in the New Health Ecosystem
7/31/13 | Pharmaceuticals & life science
Pharmaceutical companies stand ready to be tested in a world where a drug’s success is more closely tied to its performance. The challenges mount with competition from generics and growing pressure to reduce costs. Now, insurers and integrated providers are driven by models that reward health outcomes and cost savings. For success, drug makers are exploring real-world evidence, new payment models, and the right partnerships.